BIOCRYST PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 536
- Market Cap
- $1.7B
- Website
- http://www.biocryst.com
An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT02819102
- Locations
- 🇬🇧
Quotient Clinical Ltd, Ruddington, Nottingham, United Kingdom
Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT02670720
Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 74
- Registration Number
- NCT02635724
- Locations
- 🇺🇸
Peramivir Investigative Site, San Antonio, Texas, United States
🇺🇸Peramivir Investigational Site, Salt Lake City, Utah, United States
🇺🇸Peramivir investigative site, South Jordan, Utah, United States
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers
Phase 1
Completed
- Conditions
- Hereditary Angioedema
- Interventions
- Drug: Placebo to match BCX7353Drug: BCX7353
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2016-01-13
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 122
- Registration Number
- NCT02448264
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, United Kingdom
Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 137
- Registration Number
- NCT02369159
- Locations
- 🇿🇦
Peramivir Investigative Site, Pretoria, South Africa
🇺🇸Peramivir investigative site, South Jordan, Utah, United States
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430
Phase 1
Completed
- Conditions
- Filovirus InfectionsEbola Virus Infection
- Interventions
- Drug: BCX4430Drug: Placebo
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 94
- Registration Number
- NCT02319772
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, United Kingdom
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 110
- Registration Number
- NCT02303626
Study to Determine How BCX4161 is Metabolized and Eliminated by the Body
- First Posted Date
- 2014-08-18
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT02218294
- Locations
- 🇬🇧
Quotient Clinical Ltd, Ruddington, Nottingham, United Kingdom
A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT02125162
- Locations
- 🇬🇧
Quotient Clinical Ltd, Ruddington, Nottingham, United Kingdom
Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2014-08-18
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT01984788
- Locations
- 🇩🇪
Dr Inmaculada Martinez-Saguer, Morfelden-Walldorf, Germany
🇩🇪Dr Petra Staubach, Mainz, Germany
🇩🇪Dr Marcus Maurer, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath